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Argininosuccinate synthase 1 (ASS1) is the rate-
limiting enzyme for arginine biosynthesis. ASS1
expression is lost in a range of tumor types, including
50% of malignant pleural mesotheliomas. Starving
ASS1-deficient cells of argininewith arginine blockers
such as ADI-PEG20 can induce selective lethality and
has shown great promise in the clinical setting. We
have generated a model of ADI-PEG20 resistance
in mesothelioma cells. This resistance is mediated
through re-expression of ASS1 via demethylation
of the ASS1 promoter. Through coordinated tran-
scriptomicandmetabolomicprofiling,wehaveshown
that ASS1-deficient cells have decreased levels of
acetylated polyamine metabolites, together with a
compensatory increase in the expression of poly-
amine biosynthetic enzymes. Upon arginine depriva-
tion, polyamine metabolites are decreased in the
ASS1-deficient cells and in plasma isolated from
ASS1-deficient mesothelioma patients. We identify
a synthetic lethal dependence between ASS1 defi-
ciency and polyamine metabolism, which could
potentially be exploited for the treatment of ASS1-
negative cancers.INTRODUCTION
Cancer cells often rely on subversion of normal metabolic path-
ways to provide the energy and building blocks for uncontrolled
cell division. Such metabolic reprogramming is now appreciated
as an enabling hallmark of tumorigenesis and results in the up-
take of nutrients for conversion to biomass. It is becoming
increasingly appreciated that cancer cells also have altered1604 Cell Reports 16, 1604–1613, August 9, 2016 ª 2016 The Author
This is an open access article under the CC BY-NC-ND license (http://amino acidmetabolism (Tsun and Possemato, 2015). Glutamine,
serine, glycine, and arginine have all been implicated in driving
cancer cell proliferation (Amelio et al., 2014; Lind, 2004; Wise
and Thompson, 2010).
As a versatile amino acid, arginine has connections to a num-
ber of metabolic pathways pertinent to tumorigenesis, including
nitric oxide, creatine, and polyamine synthesis (Jobgen et al.,
2006; Leuzzi et al., 2008). The levels of the rate-limiting enzyme
for arginine biosynthesis, argininosuccinate synthase 1 (ASS1),
are severely reduced or absent in a number of aggressive and
chemoresistant cancers (Delage et al., 2010). The mechanisms
behind ASS1 loss are cancer type dependent. For example, in
lymphoma (Delage et al., 2012), myxofibrosarcoma (Huang
et al., 2013), nasopharyngeal carcinoma (Lan et al., 2014),
bladder cancer (Allen et al., 2014), hepatocellular carcinoma
(McAlpine et al., 2014), and malignant pleural mesothelioma
(MPM; Szlosarek et al., 2006), methylation of the ASS1 promoter
appears to mediate ASS1 repression, whereas in melanoma, the
interplay between c-Myc and HIF1a controls ASS1 levels (Tsai
et al., 2009). The reason for ASS1 downregulation in tumors is
not fully elucidated and renders the cancer cell reliant on, or ad-
dicted to, extracellular arginine. Such arginine auxotrophy has
been targeted clinically using the pegylated arginine deiminase
ADI-PEG20, a mycoplasma-derived protein that degrades argi-
nine to citrulline and ammonia (Ott et al., 2013; Synakiewicz
et al., 2014; Szlosarek et al., 2013). Starvation of arginine results
in specific cell death of ASS1-deficient cancer cells and pro-
vides a means to attack poor outcome and highly proliferative
cancers.
Approximately 50% of MPMs do not express ASS1 (Szlo-
sarek et al., 2006), making ADI-PEG20 an attractive personal-
ized therapeutic strategy (Delage et al., 2010) that has shown
significant activity in a randomized phase II trial. Encouragingly,
this trial has achieved its primary endpoint of a significant
improvement in progression free survival (PFS) above the cur-
rent standard of care (Szlosarek et al., 2013). This is the first
biomarker-driven study and first randomized trial in a decade,s.
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. TheArginineBiosyntheticPathway
Is Upregulated in Ju77R Cells
(A) Ju77S and Ju77R MPM cells were treated with
increasing concentrations of ADI-PEG20 (0, 1, 10,
100, 1,000, and 10,000 ng/ml). After 4 days of
treatment, cell viability was measured using an
ATP-based luminescence assay.
(B) Real-time qPCR analysis of RNA extracted
from Ju77S and Ju77R cells. mRNA expression
was measured using ASS1 and b-actin TaqMan
probes. b-actin was used as a control. ***p <
0.0005.
(C) Western blot analysis of protein extracted from
Ju77S and Ju77R cells. Protein expression was
analyzed using anti-ASS1, anti-ASL, and b-actin
antibodies. b-actin is used as a loading control.
(D) Real-time qPCR analysis of RNA extracted from
Ju77S and Ju77R cells. mRNA expression was
measured using ASL and b-actin TaqMan probes.
b-actin was used as a control. ***p < 0.0005.
(E) Methylation analysis across seven CpG islands
in the ASS1 promoter. Genomic DNA was ex-
tracted from Ju77S and Ju77R cells, and bisulfite
was converted. DNA was pyrosequenced across
the seven CpG islands in the ASS1 promoter.
(F) Western blot analysis of Ju77S and Ju77R cells
transfected with a non-targeting control siRNA
(siCtrl) or two siRNA oligos targeting c-Myc. Pro-
tein was extracted after 72 hr, and expression was
analyzed using anti-ASS1, anti-c-Myc, and vinculin
antibodies. Vinculin is used as a loading control.
All experiments were carried out in triplicate. For
(A), (B), and (D), error bars represent SEM. See also
Figure S1.since the publication of antifolates with cisplatin (Vogelzang
et al., 2003), to show a 50% reduction in the risk of disease
progression in MPM patients. Despite these promising
initial results, resistance to ADI-PEG20 is a clinical obstacle,
because neutralizing antibodies to ADI-PEG20 and re-expres-
sion of ASS1 in melanoma are dominant resistance mecha-
nisms (Feun et al., 2008; Long et al., 2013). However, it has
yet to be established how resistance to arginine deprivation
occurs in MPM cells.
In this study, we examined the effects of long-term arginine
deprivation on MPM cells to uncover the molecular mecha-
nisms underlying resistance to arginine deprivation. We have
generated a model of ADI-PEG20 resistance in MPM cells
whereby we observe demethylation of the ASS1 promoter,
allowing re-expression of the ASS1 transcript and protein.
Resistance was accompanied by global changes in the levels
of metabolic enzymes, resulting in greatly altered metabolic
profiles. Significantly, we found that to maintain polyamine
pools, the levels of acetylated polyamine metabolites were
decreased in ASS1-deficient cells, indicative of reduced
catabolism, together with a compensatory increase in expres-Cell Resion of polyamine biosynthetic enzymes.
Furthermore, this metabolic reprogram-
ming elucidates a synthetic lethal inter-
action between ASS1 loss and poly-amine metabolism, which could potentially be exploited for
the treatment of ASS1-negative cancers.
RESULTS
The Arginine Biosynthetic Pathway Is Upregulated to
Confer Resistance to ADI-PEG20
To investigate the metabolic adaptation of ASS1-deficient
cells upon arginine deprivation, we generated ASS1-deficient
cells resistant to the arginine-depleting drug, ADI-PEG20. The
ASS1-deficient Ju77 MPM cells were cultured in ADI-PEG20,
and over time, resistant colonies emerged (Figure 1A). Short-tan-
dem repeat analysis across 18 genetic loci confirmed that
the ADI-PEG20-resistant (Ju77R) cell line had not experienced
genetic drift and was genetically identical to the parental
ADI-PEG20-sensitive (Ju77S) cell line. To understand the mech-
anism behind the resistance, we analyzed the levels of the argi-
nine biosynthetic enzymes, ASS1 and argininosuccinate lyase
(ASL), in Ju77R and Ju77S cells. Ju77R cells had a 20-fold in-
crease in ASS1mRNA (Figure 1B) and the corresponding protein
(Figure 1C) and increased levels of ASL (Figures 1C and 1D).ports 16, 1604–1613, August 9, 2016 1605
Thus, it appears that Ju77R cells have switched on the ASS1
gene and upregulated the arginine biosynthetic pathway as an
adaptive response to arginine depletion.
Previously, we demonstrated that expression of ASS1 in
mesothelioma is regulated by methylation at CpG islands in
the ASS1 promoter, which represses transcription (Szlosarek
et al., 2006). To investigate whether changes in ASS1 promoter
methylation underlie re-expression of ASS1 in Ju77R cells, we
performed bisulfite pyrosequencing across seven CpG sites.
Upon comparison with the parental Ju77S cell line, Ju77R cells
had decreased methylation at six of seven CpG sites, and there
was an overall 5% reduction in promoter methylation (Figure 1E).
The low level of methylation in the Ju77S parental line (12%)
was quite surprising, given the absence of ASS1 mRNA (Fig-
ure 1B) and sensitivity to ADI-PEG20 (Figure 1A). We therefore
compared methylation in other ASS1-negative and ASS1-posi-
tive MPM cells to see whether this was correlated to ADI-
PEG20 sensitivity and ASS1 mRNA levels. We found an inverse
correlation between promoter methylation and mRNA level,
which in turn correlated with ADI-PEG20 sensitivity (Figures
S1A and S1B). The cell line most sensitive to ADI-PEG20,
MSTO-211H (MSTO), had 10% overall promoter methylation,
compared to 2% for the most resistant cell line, H226. Thus, it
is possible that 10% methylation represents a threshold for
methylation-induced transcriptional silencing of the ASS1 gene
in MPM cells. Previously, it has been shown in melanoma cells
that ASS1 levels can be upregulated by c-Myc to mediate resis-
tance toADI-PEG20 (Longet al., 2013; Tsai et al., 2009). To inves-
tigate whether c-Myc was involved in the re-expression of ASS1
in Ju77R cells, we analyzed c-Myc levels in the Ju77S and Ju77R
cells (Figure 1F). No difference in the expression levels of c-Myc
was observed between these cell lines. To further confirm that c-
Myc is not driving the re-expression of ASS1 in Ju77R cells, we
used two small interfering RNA (siRNA) oligos targeting c-Myc
and examined ASS1 levels (Figure 1F). We did not observe
change in ASS1 levels in the absence of c-Myc expression. Alto-
gether, our data suggest that re-expression of ASS1 in the Ju77R
cells is via demethylation of the ASS1 promoter and not through
regulation by c-Myc. The Ju77R cell line represents a cellular
model of resistance to ADI-PEG20 and demonstrates ASS1 pro-
moter demethylation in response to arginine deprivation.
ASS1 Loss Is Associated with Polyamine Metabolic
Reprogramming
To further investigate the consequences of ADI-PEG20 resis-
tance in the Ju77R cells, we assessed the metabolic response
to ASS1 re-expression and resistance to ADI-PEG20 by per-
forming untargeted metabolomic analysis using liquid chroma-
tography-mass spectrometry (LC-MS) in Ju77S and Ju77R cells.
A total of 5,220 different ion masses were detected by LC-MS,
which produced two groups by principle-component analysis
(PCA), indicating significant metabolic changes in the Ju77R
cells (Figure S2A). The metabolomic analysis showed that the
levels of the acetylated polyamines N1-acetylspermidine and
N1-acetylspermine were significantly lower in the ASS1-deficient
Ju77S cells in comparison to the ASS1-proficient Ju77R cells
(Figure 2A). Polyamines are polycations derived from arginine
that support numerous biological processes essential for cell1606 Cell Reports 16, 1604–1613, August 9, 2016survival. As such, their levels are under tight homeostatic control
through regulated synthetic and catabolic pathways. Acetylation
is the rate-limiting step in polyamine catabolism and maintains
intracellular levels through export from the cell or recycling to
putrescine (Kramer et al., 2008). The low levels of acetylated
polyamines in Ju77S cells indicated reduced catabolism, so
we measured the levels of the key enzyme responsible for poly-
amine acetylation, spermidine/spermine N1-acetyltransferase 1
(SSAT1). We observed a significant decrease in expression of
SSAT1 in the ASS1-deficient cells (Figure 2B), consistent with
our metabolomic analysis.
It has previously been shown that levels of SSAT1 can influ-
ence polyamine levels by depleting spermidine and spermine
with an increase in N1-acetylspermidine, which is subsequently
oxidatively degraded to putrescine (Mandal et al., 2013). We
therefore carried out targeted metabolomics in Ju77S and
Ju77R cells to determine whether SSAT1 levels affected poly-
amine pools. In this targeted approach, we quantified a range
of commercially obtained polyamine metabolites (putrescine,
spermine, and spermidine) and compared the spectra with
data derived from our analysis. The basal levels of putrescine
and spermine were similar in both cell lines; however, there
was a trend toward decreased baseline spermidine levels in
Ju77S cells (Figure 2C). This finding suggests that in the absence
of arginine biosynthesis, ASS1-deficient cells are unable to
maintain levels of spermidine. However, upon ADI-PEG20 treat-
ment, putrescine and spermine levels were significantly reduced
in Ju77S cells but not in Ju77R cells (p < 0.05; Figures 2D and
2E). These results suggest that in Ju77S cells, exogenous argi-
nine transported into the cell is used at least partly for polyamine
synthesis. It is therefore possible that Ju77R cells are able to
resist arginine deprivation-induced changes in polyamine levels
through their ability to endogenously synthesize arginine and
subsequently have a reduced reliance on extracellular arginine.
To determine whether these changes in polyamine synthesis
following arginine depletion were specific to the Ju77 cell lines,
we performed targeted metabolomics on two other ASS1-nega-
tive cell lines, in addition to Ju77 cells. All ASS1-deficient cells
showed a significant reduction in spermine levels upon arginine
depletion (p < 0.0005; Figure 2F). This reduction in polyamine
levels suggests exogenous arginine is required to maintain poly-
amine biosynthesis in MPM cells lacking ASS1.
Next, we investigated whether these changes in polyamine
metabolites were also occurring in ASS1-deficient mesotheli-
oma patients treated with ADI-PEG20. To this end, we obtained
plasma samples from the ADAM (arginine deiminase and meso-
thelioma) trial, which is a randomized phase II study of ADI-
PEG20 and best supportive care versus best supportive care
alone in patients with ASS1-deficient mesothelioma patients
(ClinicalTrials.gov no. NCT01279967). Our analysis included
ASS1-deficient, control mesothelioma patients receiving best
supportive care alone (n = 6) and ASS1-deficient mesothelioma
patients either with stable disease or partial response (SD/PR;
n = 17) or with mixed response or progressive disease (MR/
PD; n = 11) after ADI-PEG20 treatment and best supportive
care. As expected, we observed a significant decrease in argi-
nine levels (Figure 3A) and a subsequent significant increase in
citrulline levels (Figure 3B) after ADI-PEG20 treatment in plasma
Figure 2. Polyamine Metabolic Reprogram-
ming in ASS1-Deficient Cells
(A) Untargetedmetabolic analysiswasperformedon
the Ju77S and Ju77R cells. The acetylated poly-
aminesN1-acetylspermineandN1-acetylspermidine
were identified as significantly decreased in the
Ju77S cells. The graph represents the log2-fold
change in comparison to levels in the Ju77S cells.
(B) Real-time qPCR analysis of RNA extracted
from Ju77S and Ju77R cells. mRNA expression
was measured using SSAT1 and b-actin TaqMan
probes. b-actin was used as a control. ***p <
0.0005.
(C) Targeted metabolic analysis was performed on
the Ju77S and Ju77R cells upon comparison to
the commercially available polyamine metabolites
putrescine, spermidine, and spermine. The graph
represents the absolute level of each metabolite (in
micrograms per milliliter).
(D and E) Targeted metabolic analysis was per-
formed on the Ju77S and Ju77R cells before and
after 24 hr of treatment with ADI-PEG20 (750 ng/ml)
upon comparison to the commercially available
polyamine metabolites putrescine (D) and sper-
mine (E). The graph represents the absolute level
of eachmetabolite (inmicrogramspermilliliter). *p<
0.05.
(F) Targeted metabolic analysis was performed
on the ASS1-deficient Ju77, 2591, and T24 cells
before and after 24 hr of treatment with ADI-PEG20
(750 ng/ml) upon comparison to the commer-
cially available polyamine metabolite spermine.
The graph represents the level in comparison to
mock (PBS) treated cells. ***p < 0.0005.
See also Figure S2A.from ASS1-deficient mesothelioma patients. Upon analysis, we
could detect the polyamine putrescine, but not spermine and
spermidine, from all plasma samples. These observations corre-
latewith other studies indicating low levels of spermine and sper-
midine compared to putrescine in plasma (Liu et al., 2013;
Magnes et al., 2014). We observed a significant reduction of pu-
trescine in plasma samples from ASS1-deficient mesothelioma
patients with SD/PR after ADI-PEG20 treatment and best sup-
portive care (p < 0.0002; Figure 3C). No decrease in putrescine
levels was observed in ASS1-deficient control patients or
ASS1-deficient mesothelioma patients with MR/PD after treat-
ment. These data strongly support our in vitro data that poly-
amine levels are decreased upon ADI-PEG20 treatment in
ASS1-deficient cells. Significantly, we show that ADI-PEG20
treatment canmodulate polyamine levels both in vitro and in vivo,
thus suggesting that polyamine disruption may be an additional
mechanism of action of this therapeutic.Cell ReIncreased Expression of Polyamine
Synthesis Genes in ASS1-Deficient
Cells
Our results suggest that in the absence
of ASS1 and upon arginine deprivation,
MPM cells are unable to maintain their
levels of polyamine metabolites. To better
understand this metabolic reprogram-ming, we analyzed the global transcriptomic changes that
accompany these metabolic alterations. Comparative gene
expression analysis of the Ju77S and Ju77R cells was performed
using microarrays (Figure S3). This identified 234 differentially
expressed genes with a greater than 2-fold difference (adjusted
p < 0.05). Many of these differentially expressed genes have crit-
ical roles in nutrient uptake, amino acid metabolism, one-carbon
metabolism, glycolysis, and nucleotide biosynthesis. As ex-
pected, ASS1 was identified as significantly upregulated in
Ju77R cells, serving as an internal control for themicroarray anal-
ysis. In addition, the microarray data highlighted several features
that allow the ASS1-negative Ju77S cells to sustain arginine
auxotrophy. Ju77S cells have increased expression of the argi-
nine transporters SLC7A2 and SLC3A2, indicating an increased
reliance on arginine transport from the extracellular environment
(Figure 4A). This is consistent with the dependence on extracel-
lular arginine for survival in the absence of ASS1 expression.ports 16, 1604–1613, August 9, 2016 1607
Figure 3. Reduced Putrescine Levels in
Plasma from ASS1-Deficient Mesotheli-
oma Patients with SD/PR after ADI-PEG20
Treatment
(A and B) Untargeted metabolic analysis was per-
formed on plasma isolated from ASS1-deficient
mesothelioma patients before and after ADI-PEG20
treatment and best supportive care. Arginine me-
tabolites (A) and citrulline metabolites (B) were
identified in plasma from all patients and were
significantly decreased and increased after ADI-
PEG20 treatment, respectively. The graphs repre-
sent the detected concentration (in micromolars) of
arginine (A) and citrulline (B). ***p < 0.0001.
(C) Untargeted metabolic analysis was performed
on plasma isolated from control ASS1-deficient
mesothelioma patients before and after best sup-
portive care alone (n = 6) and ASS1-deficient me-
sothelioma patients with either SD/PR (n = 17) or
MR/PD (n = 11) after ADI-PEG20 treatment and
best supportive care. The polyamine putrescine
was identified in plasma from all patients and was
only significantly decreased in the ASS1-deficient
patients with SD/PR after ADI-PEG20 treatment
and best supportive care. The graph represents
the mean centered putrescine peak area. ***p <
0.0002.
See also Figure S2B.Several enzymes involved in polyamine metabolism had a sig-
nificant increase in expression in the ASS1-deficient Ju77S cells
(Figures 4B and 4C). These include the rate-limiting enzyme
in polyamine biosynthesis ornithine decarboxylase (ODC1), ad-
enosylmethionine decarboxylase 1 (AMD1), spermine synthase
(SMS), spermine oxidase (SMOX), and agmatinase (AGMAT;
Figure 4D). Real-time qPCR validation experiments confirmed
consistent increased expression of genes involved in polyamine
biosynthesis in ASS1-deficient cells by real-time qPCR (Fig-
ure 4B). ODC1 was observed to be significantly increased in
the panel of ASS1-negative cells in comparison to the ASS1-
positive MPM cells (Figure 4C), suggesting that the increase in
expression of polyamine metabolic enzymes may be a general
feature of ASS1 loss rather than a specific effect in Ju77 cells.
Altogether, our results suggest that ASS1-deficient cells main-
tain their polyamine pools by decreased catabolism and
increased synthesis through upregulation of polyamine biosyn-
thetic enzymes.
ASS1-Deficient Cells Are Synthetically Lethal with
Polyamine Inhibition
Our data suggest that the inability of ASS1-deficient cells to syn-
thesize arginine results in a compensatory increase in polyamine
biosynthetic enzymes and a decrease in polyamine catabolism in
an effort to maintain polyamine pools. Furthermore, these pools
are susceptible to perturbation by arginine deprivation. We1608 Cell Reports 16, 1604–1613, August 9, 2016therefore hypothesized that ASS1-defi-
cient cells may be reliant on expression
of these metabolic enzymes for survival.
To investigate this, we treated Ju77S
and Ju77R cells with the irreversibleODC1 inhibitor D,L-a-difluoromethylornithine (DFMO; Figure 4D)
to block polyamine biosynthesis and analyzed cell viability after
4 days (Figure 5A). Significantly, we observed an increased
sensitivity in the ASS1-deficient cells to DFMO treatment (p <
0.0005) in comparison to the ASS1-proficient cells, suggesting
a synthetic lethal interaction between ASS1 loss and inhibition
of polyamine synthesis. To further investigate this, we treated a
panel of ASS1-deficient and ASS1-proficient MPM cells with
increasing concentrations of DFMO and analyzed cell viability
(Figure 5B). Significantly, we observed increased sensitivity in
the ASS1-deficient cells in the panel of MPM cell lines (p <
0.0005), suggesting that ASS1-deficient cells are reliant on the
increase in polyamine metabolic gene expression for survival.
To determine whether this sensitivity was due to polyamine
depletion, rather than an off-target effect on arginine levels, we
treated Ju77S, Ju77, and MSTO cells with DFMO in addition to
ornithine, putrescine, or arginine (Figure 5C). Our data show
that addition of polyamines, but not arginine, can rescue the
synthetic lethal effect with DFMO treatment, confirming that
this sensitivity is specifically due to polyamine depletion (p <
0.0005). To further investigate this synthetic lethal relationship,
we next determined whether addition of DFMO to ADI-PEG20
treatment could have a synergistic effect by performing combi-
nation index (CI) experiments. Combination studies were carried
out over the range of drug concentrations, and the CI values
were calculated using CalcuSyn software (Table 1). CI = 1
Figure 4. Expression of Polyamine Meta-
bolic Enzymes Are Increased in ASS1-Defi-
cient Cells
(A and B) Real-time qPCR analysis of RNA ex-
tracted from Ju77S and Ju77R cells. (A) mRNA
expression was measured for the arginine trans-
porter genes using SLC7A2, SLC3A2, and b-actin-
specific TaqMan probes. (B) mRNA expression
was measured for the polyamine metabolic en-
zymes using ODC1, SMOX, AMD1, AGMAT, SMS,
and b-actin-specific TaqMan probes. b-actin was
used as a control. *p < 0.05, **p < 0.005, ***p <
0.0005.
(C) Real-time qPCR analysis of RNA extracted from
a panel of ASS1-deficient (MSTO and Ju77S) and
ASS1-proficient (H28, H226, and Ju77R) MPM cell
lines. mRNA expression was measured for the
polyamine metabolic enzyme, ODC1, and b-actin
using gene-specific TaqMan probes. b-actin was
used as a control. **p < 0.005 upon comparison of
the ASS1ve cell lines (MSTO and Ju77S) versus
the ASS1+ve cell lines (H28, H226, and Ju77R).
(D) Schematic representation of key enzymes and
their roles in the urea cycle, polyamine synthesis,
and polyamine catabolism. These enzymes are
ASS1, ASL, arginine (ARG), ODC1, AGMAT, sper-
midine synthase (SRM), SMS, AMD1, SSAT1,
SMOX, and polyamine oxidase (PAO).
For (A)–(C), experiments were carried out in tripli-
cate and error bars represent SEM. See also
Figure S3.indicates an additive effect between two drugs, whereas CI < 1
or CI > 1 indicates synergism or antagonism, respectively. We
observed that a combination of DFMO+ADI-PEG20 is synergis-
tic upon treatment with these drugs at specific concentrations
(10 mg/ml ADI-PEG20 + 10 nM DFMO and 100 mg/ml ADI-
PEG20 + 100 nM DFMO).
Altogether, our data suggest that in ASS1-deficient cells, poly-
amine levels are maintained by a compensatory increase in
expression of polyamine biosynthetic enzymes and a decrease
inpolyamine catabolism. The increased relianceofASS1-deficient
cells on these pathways has uncovered a vulnerability that can be
exploited therapeutically by arginine and/or polyamine depletion.
DISCUSSION
MPM is a highly chemoresistant cancer associated with poor
prognosis. Approximately 50% of MPMs do not express ASS1,Cell Remaking them sensitive to arginine-
depriving agents such as ADI-PEG20.
This personalized therapeutic strategy
has shown activity in a randomized phase
II trial (Szlosarek et al., 2013). However,
resistance to ADI-PEG20 remains a signif-
icant clinical problem, and its precise
mechanism has yet to be thoroughly
investigated. We have generated a model
of resistance to arginine deprivation in
MPM cells that is characterized by deme-thylation of the ASS1 promoter and re-expression of ASS1. Me-
tabolomic and transcriptomic profiling of these cells uncovered a
previously unappreciated connection between ASS1 loss and
polyamine metabolism, a finding we were able to confirm in
MPM patients undergoing arginine deprivation therapy. Our
data suggest that targeting polyamine synthesis using the clini-
cally available polyamine inhibitor DFMO may provide a thera-
peutic strategy for the treatment of ASS1-negative MPMs.
DFMO is clinically approved for the treatment of African trypano-
somiasis and hirsutism and is in clinical trials as both a chemo-
therapeutic and a chemopreventative agent in a number of
malignancies. Future studies will determine whether combinato-
rial treatment with ADI-PEG20 and DFMO can overcome the
generation of resistance to arginine deprivation by simulta-
neously targeting two compensatory metabolic pathways.
Significantly, ASS1 loss not only occurs in MPM tumors but
also is a feature of numerous other tumor types, suggestingports 16, 1604–1613, August 9, 2016 1609
Figure 5. Inhibition of Polyamine Synthesis
Is Synthetically Lethal in ASS1-Deficient
MPM Cells
(A and B) Ju77S and Ju77R MPM cells (A) and a
panel of ASS1-deficient (MSTO and Ju77) and
ASS1-proficient (H28 and H226) MPM cell lines (B)
were treated with increasing concentrations of the
polyamine inhibitor DFMO (0, 1, 10, 100, and
1,000 mM). After 4 days of treatment, cell viability
was measured using an ATP-based luminescence
assay.
(C) The Ju77, Ju77S, and MSTO cells were treated
with mock (DMSO; 0.01%), DFMO (1,000 mM),
DFMO and ornithine (Orn; 5 mM), DFMO and
arginine (Arg; 5 mM), or DFMO and putrescine (Put;
0.1mM). After 4 days of treatment, cell viability was
measured using an ATP-based luminescence
assay.
***p < 0.0005. Experiments were carried out in
triplicate, and error bars represent SEM.this therapeutic combination may extend beyond treatment of
MPM. Additional studies are required to elucidate the full poten-
tial of this therapeutic strategy.
The concept of synthetic lethality has provided a means to
exploit specific genetic vulnerabilities in cancer cells that can
be targeted for the development of personalized therapeutics.
In this study, we describe a synthetic lethal relationship between
loss of ASS1 and inhibition of polyamine synthesis. Previously,
others have shown that synthetic lethal interactions can occur
between different compensating metabolic pathways. Inhibition
of heme oxygenation is synthetically lethal in fumarate hydra-
tase-deficient hereditary leiomyomatosis and renal-cell cancerTable 1. CI Values of Combined Treatment of ADI-PEG20 and
DFMO at Specified Concentrations, Calculated with CalcuSyn
Software, for Ju77S and Ju77R Cells
Cell Line ADI-PEG20 (mg/ml) DFMO (nM) CI
Ju77S 10 10 0.368
100 100 0.499
Ju77R 10 10 0.418
100 100 0.581
1610 Cell Reports 16, 1604–1613, August 9, 2016(HLRCC) cells (Frezza et al., 2011a). In
addition, a nicotinamide adenine dinucle-
otide (NAD+) synthesis inhibitor induces
synthetic lethality in lactose dehydroge-
nase-A-deficient tumor cells (Le et al.,
2010). Studies have also shown that
dual inhibition of two energy-producing
pathways, using metformin and the
glycolysis inhibitor 2-deoxyglucose, re-
sults in a synthetic lethal interaction in
in vivo tumor mouse models (Cheong
et al., 2011). Advances in high-throughput
genomic technologies have greatly in-
creased our understanding of the ge-
netics of tumor cells and have identifiednumerous mutations in metabolic enzymes, including isocitrate
dehydrogenase 1, fumarate hydratase, and succinate dehydro-
genase, in a range of tumor types (Frezza et al., 2011b; King
et al., 2006; Muller et al., 2012; Tomlinson et al., 2002; Yan
et al., 2009). Elucidation of these metabolic deficiencies high-
lights compensatory metabolic pathways that may be targeted
through a synthetic lethal strategy.
Loss of ASS1 has been described for numerous tumor types,
including MPM; consequently, ASS1 has been confirmed as a
bona fide tumor suppressor gene. However, despite increasing
interest in the role of ASS1, the overall functional significance
of ASS1 loss in carcinogenesis has yet to be fully elucidated. Ra-
binovich et al. (2015) described diversion of aspartate for thymi-
dine synthesis as a major consequence of ASS1 loss leading to
enhanced tumor cell proliferation. Polyamines affect numerous
processes in carcinogenesis, including increasing cell prolifera-
tion, modulating apoptosis, and increasing expression of genes
affecting tumor invasion and metastasis (Gerner and Meyskens,
2004). Increased polyamine levels have been reported in many
tumor types (Gerner and Meyskens, 2004), and overexpression
of ODC1 was identified as a potential biomarker of colorectal
cancer risk and progression (Brabender et al., 2001; McGarrity
et al., 1990; Wang et al., 1996). In addition, numerous studies
have shown that polyamines have the ability to regulate expres-
sion of a number of oncogenes (Bachrach et al., 2001; Tabib
and Bachrach, 1999). All these observations suggest that the
deregulated polyamine metabolism resulting from ASS1 loss
described herein may be partly driving the tumorigenic pheno-
type of these cells and contributing to the tumor suppressive
function of ASS1.
In addition to uncovering a dependence on polyamine synthe-
sis in ASS1-deficient tumor cells, our results point to a potential
mechanism of resistance to ADI-PEG20, with demethylation
driving ASS1 upregulation. Studies of tumor tissue and/or
plasma from trials of patients with MPM undergoing arginine
deprivation will be critical to assessing the relevance of these
findings in the clinic. Based on our data, putrescine levels may
be used as an early response marker, predicting those patients
likely to respond to ADI-PEG20 treatment. Moreover, ASS1 re-
expression is likely to modulate sensitivity to alternative drugs
and drug combinations, the study of which is possible by the
availability of the Ju77S and Ju77R cell lines.
Altogether, we have elucidated a compensatory metabolic
network in tumor cells such that in the absence of the arginine
biosynthetic enzyme ASS1, the polyamine metabolic pathway
is upregulated. Collectively, our data suggest that this increase
in polyamine metabolic gene expression drives cellular prolifera-
tion in ASS1-deficient cells and can be exploited clinically
through the use of polyamine inhibitors.
EXPERIMENTAL PROCEDURES
Cell Culture
MSTO, Ju77, H28, and H226 cell lines were purchased from ATCC and
routinely grown in RPMI-1640 media (Sigma-Aldrich) supplemented with
10% fetal bovine serum (FBS; Invitrogen), 100 U/ml penicillin, and 100 mg/ml
streptomycin at 37C/5% CO2. Cell lines were authenticated by short-tandem
repeat (STR) profiling (DNA Diagnostics Centre). The compounds ADI-PEG20
(Polaris Pharmaceuticals) and DFMO (Santa Cruz) were obtained commer-
cially. To generate Ju77R, 1 3 106 Ju77 cells were incubated with 10 mg/ml
ADI-PEG20 in RPMI-1640 media supplemented with 2% FBS and re-treated
every week. After approximately 2 months, colonies were picked and seeded
in a 96-well plate with 10 mg/ml ADI-PEG20. A surviving clone (Ju77R) was
gradually expanded and maintained in 1 mg/ml ADI-PEG20.
ADI-PEG20 Cell Viability Assays
Cells were seeded in 96-well plates (13 103 to 23 103 cells/well) 24 hr before
treatment with ADI-PEG20 serially diluted in RPMI-1640 media containing 2%
dialyzed FBS. After 4 days, cell viability was assessed with the ATP-based,
luminescence assay CellTiter-Glo (Promega).
Western Blot
Cells were lysed in 20 mM Tris (pH 8), 200 mM NaCl, 1 mM EDTA, 0.5% (v/v)
tergitol-type NP-40 (NP40), and 10% glycerol supplemented with protease
inhibitors (Roche). Equivalent amounts of protein were electrophoresed on
4%–12% Novex precast gels (Invitrogen) and transferred to nitrocellulose
membrane. After blocking for 1 hr in 13 Tris-buffered saline/5% non-fat dried
milk, membranes were incubated overnight at 4C in primary antibody,
including anti-ASS1 (HPA020934, Sigma-Aldrich), anti-ASL (HPA016646,
Sigma-Aldrich), anti-c-Myc (#5650, Cell Signaling Technology [CST]), anti-vin-
culin (#4650, CST), and anti-b-actin-HRP (#4970, CST). Membranes were
incubated with anti-immunoglobulin G-horseradish peroxidase and visualized
by chemiluminescent detection (Supersignal West Pico Chemiluminescent
Substrate, Pierce). Immunoblotting for b-actin or vinculin was performed as
a loading control.siRNA Transfections
For siRNA transfections, cells were transfected with individual siRNA oligonu-
cleotides (QIAGEN) using Lipofectamine RNAiMax (Invitrogen) according to
the manufacturer’s instructions. As a control for each experiment, cells were
left untransfected or transfected with a non-targeting control siRNA and
were concurrently analyzed.
Methylation Analysis
Genomic DNA was isolated from 1 3 106 cells using a DNeasy kit (QIAGEN).
Then, 500 ng was bisulfite converted using the EZ DNA methylation kit (Zymo
Research). Pyrosequencing was performed using the PyroMark ID System
(Biotage). The primers used for amplification of bisulfite-treated DNAs were
designed to cover a region including seven CpG sites of the ASS1 promoter.
The primers were 50-biotin-TGTGTTTATAATTTGGGATGG-30 (forward primer)
and 50-CCTCCTCCTCTAAACCC-30 (reverse primer), which amplified a 145 bp
region. PCR was performed in a final volume of 30 ml containing 0.5 mM of
each primer, 200 mmol/L of each dinucleotide triphosphate, 0.05 units of Ampli-
TaqGold 360DNApolymerase in buffer containing 1.5mmol/lMgCl2, 3 ml of 360
GC Enhancer (Applied Biosystems), and 2 ml of bisulfite-treated DNA as a tem-
plate. The initial denaturation step (95C, 10 min) was followed by 35 cycles of
30 s at 95C, 30 s at 52C, and 40 s at 72Cand a final extension step at 72C for
10 min. Then, 3 ml of the PCR products were visualized by gel electrophoresis
and 25 ml were subjected to pyrosequencing using the reverse sequencing
primer at a final concentration of 0.5 mM. Purification and subsequent process-
ing of the biotinylated single-strand DNA was done according to the manufac-
turer’s instructions using the Pyro Gold reagents kit (Biotage). Resulting data
were analyzed and quantified with the PyroMark CpG Software (Biotage). Pos-
itive (commercial methylated DNA) and negative (placenta DNA) controls were
included and treated, as well as samples. Pyrograms of the control DNA were
analyzed to confirm complete bisulfite conversion.
Real-Time qPCR
RNA was extracted from cells using either the TRIzol Reagent (Life Technolo-
gies) or the RNeasy kit (QIAGEN) and quantified using a Nanodrop spectro-
photometer (Thermo Scientific). Then, 500 ng of RNA was reverse transcribed
using the Omniscript cDNA synthesis kit (QIAGEN) and 1ml of cDNA was used
in each qPCR reaction. Multiplex PCR was performed on an ABI Prism 7500
Real-Time PCR Instrument (Applied Biosystems), and data were analyzed
using the DDCt method. TaqMan probes were purchased from Applied
Biosystems.
Gene Expression Microarray Analysis
The 2 3 105 cells were plated in a 6-well plate, and RNA was extracted the
following day using the RNeasy kit. Quantification and quality control of RNA
were performed on the Nanodrop spectrophotometer and an Agilent Bio-
analyser (Agilent Technologies), respectively. Global gene expression profiling
was performed on an Illumina HT12v4 array at the Genome Centre (Queen
Mary University of London). Raw image files were processed and analyzed
in Illumina BeadStudio. This was followed by quality control and normalization
of array data using the upgraded version of the O-miner transcriptomics
analysis platform (Cutts et al., 2012) adapting the Lumi R Bioconductor pack-
age (https://www.bioconductor.org/packages/release/bioc/html/lumi.html).
Differential expression analysis was performed using Limma (Ritchie et al.,
2015), and the p values were further adjusted using the Benjamini and Hoche-
berg procedure (Benjamini and Hochberg, 1995). Significantly differentially ex-
pressed genes were further identified using a double threshold of the adjusted
value of p < 0.05 and the absolute value of fold change > 2. Gene expression
data have been deposited at GEO: GSE73970.
Metabolomic Analysis
For the untargeted metabolomics, 100 ml of plasma were extracted with 300 ml
of methanol containing 0.1% formic acid. Intracellular metabolites were
extracted from 5 3 106 cells using 80% methanol containing 1% formic
acid. After vortexing, samples were incubated on ice for 30 min and then
centrifuged at 10,000 3 g for 10 min at 4C. The supernatant was transferred
and evaporated under SpeedVac (Savant, Thermo Scientific). Dried extracts
were reconstituted in 50 ml of 10% acetonitrile (containing 0.1% formic acid),Cell Reports 16, 1604–1613, August 9, 2016 1611
and 10 ml were injected into the ultra-high performance liquid chromatography
(UPLC)-mass spectrometry (MS) system. UPLC-MS was used to quantify the
intracellular metabolites as described (Pandher et al., 2009). For the targeted
metabolomics, metabolites were extracted from cells (1 3 106) using an
80% methanol solution. Samples were mixed and incubated on ice for
30 min. After centrifuging, supernatant was separated and evaporated in a
SpeedVac. Dried extracts were reconstituted in 50 ml of 85% acetonitrile (con-
taining 0.5% acetic acid), and 10 ml were injected into the UPLC-tandemmass
spectrometry (MS/MS) system. The method used to quantify putrescine, sper-
mine, and spermidine was according to Shin et al. (2011).
Patient Plasma Samples
Plasma samples were collected from patients with mesothelioma after written
informed consent at St. Bartholomew’s Hospital. The protocol was approved
by the East London and City Research Ethics Committee. All studies comply
with the rules of the review board and by the revised Helsinki protocol. The sam-
ples were collected at baseline and after ADI-PEG20 treatment and best sup-
portive care or best supportive care alone weekly over 9 weeks of treatment.
Analysis of Drug Combination
Drug synergy was determined by the CImethod using CalcuSyn software (Bio-
soft). Data obtained from the growth inhibitory experiments were used to
perform these analyses. The CImethod is amathematical and quantitative rep-
resentation of a pharmacologic interaction between two drugs. Using growth
inhibitory data and computerized software, CI values were generated over a
range of 0.05–0.90 (reflecting 5%–90% growth inhibition). CI = 1 indicates
an additive effect between two drugs, whereas CI < 1 or CI > 1 indicates syn-
ergism or antagonism, respectively.
Statistical Analysis
Unless stated otherwise, data represent SEM of at least three independent ex-
periments. The two-tailed paired Student’s t test was used to determine statis-
tical significance, with p < 0.05 regarded as significant.
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